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Statement of findings
The fibroblast growth factor receptor (FGFR)2 gene has been shown to be amplified in
5–10% of breast cancer patients. A breast cancer cell line developed in our laboratory,
SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2
message was found to be overexpressed 40-fold in SUM-52PE cells as compared with
normal human mammary epithelial (HME) cells. Both human breast cancer (HBC) cell lines
and HME cells expressed two FGFR2 isoforms, whereas SUM-52PE cells overexpressed
those two isoforms, as well as several unique FGFR2 polypeptides. SUM-52PE cells
expressed exclusively FGFR2-IIIb isoforms, which are high-affinity receptors for fibroblast
growth factor (FGF)-1 and FGF-7. Differences were identified in the expression of the
extracellular Ig-like domains, acid box and carboxyl termini, and several variants not
previously reported were isolated from these cells.
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(cell); HBC = human breast cancer (cell); PCR = polymerase chain reaction; RT = reverse transcription.
Introduction: The FGFR family of receptor tyrosine kinases
includes four members, all of which are highly alternatively
spliced and glycosylated. For FGFR2, alternative splicing of the
second half of the third Ig-like domain, involving exons IIIb and
IIIc, is a mutually exclusive choice that affects ligand binding
specificity and affinity [1–3]. It appears that the second half of
the third Ig-like domain can dictate high affinity for FGF-2 or
keratinocyte growth factor (KGF), whereas affinity for FGF-1
appears to remain the same [3]. Alternative splicing of the
carboxyl terminus has been shown to involve at least two
different exons that can produce at least three different variants.
The C1-type and C2-type carboxyl termini are encoded by the
same exon, and have two different splice acceptor sites,
whereas the C3-type carboxyl terminus is encoded by a
separate exon [4]. The biologic significance of the C1 carboxyl
terminus, as compared with the shorter C3 variant found
primarily in tumorigenic samples, has been studied in NIH3T3
transfection assays, in which C3 variants were able to produce
three times more transformed foci in soft agar than C1 variants
(both IIIb), whereas full length FGFR2 and FGFR1 (both IIIc
variants) showed no transforming activity [4].
Previous studies [5,6] have found amplification and
overexpression of FGFR2 in 5–10% of primary breast cancer
specimens. A recent study [7] done using a tissue array
consisting of 372 primary breast cancer specimens found a
5% incidence of FGFR2 amplification. To our knowledge,
none of the HBC cell lines studied thus far have an FGFR2
gene amplification, although overexpression of FGFR2
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Introduction
The FGFs are a family of polypeptides consisting of 18 dif-
ferent growth factors that bind with varying specificity and
affinity to four different FGFRs. FGFs stimulate prolifera-
tion of a wide variety of cells of mesenchymal, neuronal,
and epithelial origins [15,16], and have been found [17] to
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message and protein has been documented for some breast
cancer cell lines [6,8,9].
SUM-52PE is a breast cancer cell line previously isolated in our
laboratory that grows under serum-free and epidermal growth
factor-free conditions, has high levels of tyrosine-
phosphorylated membrane proteins, and has the capacity to
invade and grow under anchorage-independent conditions
[10–12]. This cell line exhibits all of the important hallmarks of
transformed, highly malignant cells. Therefore, SUM-52PE was
used as a model to study the diversity of FGFR2 expression in
a breast cancer cell line that has true amplification and
overexpression of FGFR2.
Objectives: This study was conducted to examine the degree
of FGFR2 amplification and overexpression in the breast
cancer cell line SUM-52PE. Subsequent sequencing and
characterization of individual FGFR2 variants cloned from the
SUM-52PE cell line was completed to determine the
complexity of FGFR2 alternative splicing in the context of a
highly metastatic breast cancer cell line.
Methods: Southern, Northern and Western blot analyses were
done in order to determine the degree of FGFR2 amplification
and overexpression in the breast cancer cell line SUM-52PE.
Individual FGFR2 variants were cloned out of SUM-52PE using
FGFR2-specific primers in a reverse transcription (RT)
polymerase chain reaction (PCR). FGFR2 cDNAs were
characterized by restriction fragment analysis, sequencing and
transient transfection into 293 cells to examine the protein
expression of each FGFR2 clone.
Results: The results of the Southern blot showed that there
was a 12-fold amplification of FGFR2 in the SUM-52PE cell
line. Northern blot analysis of SUM-52PE showed FGFR2
transcripts to be highly overexpressed compared with other
breast cancer cell lines and normal HME cells. Several
overexpressed bands of approximately 6.3, 5.0, 4.0, and 2.8 kb
were observed in SUM-52PE cells. The most prominent band,
at 2.8 kb, was so abundant that it was difficult to discern other
individual bands clearly. Western blot analysis showed that
both normal HME and HBC cells expressed two FGFR2
variants of 95 and 135 kDa. The SUM-52PE cell line greatly
overexpressed not only these two polypeptides, as compared
with HME and HBC cells, but also overexpressed two unique
variants of FGFR2 – 85 and 109 kDa polypeptides – as well as
several smaller polypeptides in the 46–53 kDa range. The
antibody used in Western blot analysis only recognizes FGFR2
isoforms that express the C1 carboxyl termini, therefore greatly
underestimating the actual number of different FGFR2 variants
that are overexpressed in this cell line.
PCR was performed to determine the proportion of C1/C2
variants as compared with C3 variants in the SUM-52PE cell
line. Results of this analysis indicated the presence of all three
types of variants in this cell line, although the C1/C2 variants
were predominant as compared with the C3 variants in
SUM-52PE.
Four different FGFR2-C1 clones were isolated and sequenced
from SUM-52PE cells, which differed in their signal sequence,
first Ig-like loop, and acid box. Two FGFR2-C2 clones were
isolated from the SUM-52PE cell line, which were identical to
each other except for the variable expression of the number of
Ig-like domains (two or three). Three C3 clones were isolated
and sequenced, two of which have not previously been
described in the literature. Clone C3-#3 contained two Ig-like
domains, but no acid box. C3-#5 was missing the first two
Ig-like domains and the acid box, but did contain the third
Ig-like domain.
Discussion: There is an extensive amount of evidence
implicating erbB-2, a gene that is overexpressed in
approximately 30% of breast cancer cases, as a breast cancer
gene [13]. The identification of other breast oncogenes that
function in the remaining 70% of cases is an ongoing
challenge, as is establishing a causal role for such oncogenes
in HME cell transformation.
FGFR1 and FGFR2, previously established oncogenes, were
found to be amplified within large amplicons on 8p11 and
10q26, respectively, in the breast cancer cell line SUM-52PE
[14]. Previous studies have shown that the FGFR2 gene is
amplified in about 5–10% of breast cancer cases.
Our results showed that SUM-52PE cells overexpressed many
alternatively spliced isoforms of FGFR2 at both the transcript and
protein level as compared with normal HME cells. The variability
in FGFR2 isoform expression is complex and involves exon IIIb/c,
which encodes the second half of the third Ig-like loop; variations
in the carboxyl terminal end of the receptor, involving the C1/C2
or C3 domains; and variable expression of the Ig-like loops and
acid box in the extracellular portion of the receptor. The
characterization of three unique FGFR2 isoforms that were
cloned from SUM-52PE may build on the findings of others
concerning the transforming potential of FGFR2 variants [4]. In
particular, because it has been demonstrated that expression of
C3-IIIb variants may have more transforming activity than C1-IIIb
variants, differences between the three C3 clones we have
isolated may provide information regarding the influence of
particular structural domains on transforming potential.
Ongoing studies are aimed at characterizing the transforming
ability of FGFR2 isoforms obtained from SUM-52PE cells by
transducing these genes into normal HME cells. By
overexpressing FGFR2 isoforms in a physiologically relevant
system, we hope to determine the isoform(s) that acts in a
dominant way in the process of cell transformation, and to
determine whether different regions present in individual clones
drive specific phenotypes associated with transformation.
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induce, inhibit, and maintain cell differentiation in different
experimental systems. In addition, FGFs have been shown
to be involved in neuronal survival [18], and stimulation of
angiogenesis [19] and embryogenesis [20].
The FGFRs are a family of receptors that are characterized
by the presence of two or three Ig-like domains and an
acid box in the extracellular domain, a transmembrane
region, and a split kinase domain in the cytoplasmic
domain of the molecule [17]. Binding of FGF to heparin, or
cell-surface heparin sulfate proteoglycans, results in high-
affinity binding of this complex to FGFRs [219]. FGFRs
subsequently undergo dimerization, followed by transphos-
phorylation on cytoplasmic tyrosine residues [22,23].
FGFRs can be alternatively spliced into a variety of isoforms
that may have different functions. For example, at the amino
terminus, which encodes the ectodomain of the receptor,
alternative splicing of exon III results in the synthesis of
either the IIIb or IIIc versions of FGFR2, which differ in their
ligand specificities. FGFR2-IIIb, also referred to as KGF
receptor, has been shown to be a high-affinity receptor for
KGF, whereas FGFR2-IIIc receptors have a high affinity for
FGF-2. At the carboxyl terminus, FGFR2 can be alterna-
tively spliced to produce three different variants from two
different exons [4]. C1/C2 variants are produced from the
same exon with two different splice acceptor sites. C3 vari-
ants are produced from a separate exon with a different 3′-
noncoding region from that of C1/C2 variants, resulting in a
shorter form of FGFR2, which has been found [4] to be the
predominant variant in stomach cancer cell lines as com-
pared with normal stomach tissue.
Overexpression and amplification of growth factor recep-
tors are common alterations observed in HBC cells. The
FGFR1 and FGFR2 genes are expressed in both normal
and breast cancer tissues [24], and alterations, including
amplification and overexpression of FGFR1 and FGFR2,
have previously been reported in 5–10% of primary breast
cancer specimens [5,6]. A recent study [7] that was done
using a tissue array consisting of 372 primary breast spec-
imens found a 5% incidence of FGFR2 amplification.
There are at least four studies [6,8,9,24] that have ana-
lyzed the presence of FGFR2 message in breast cancer
cell lines. These studies show great discrepancy as to the
presence or absence of FGFR2 message and level of
expression, possibly due to the method of detection
(RT-PCR, Northern blot, or ribonuclease protection
assay). To our knowledge, none of the HBC cell lines
studied thus far have FGFR2 gene amplification, although
overexpression of FGFR2 message and protein has been
documented for some breast cancer cell lines [6,8,9].
SUM-52PE is a breast cancer cell line previously isolated
in this laboratory that grows under serum-free and
epidermal growth factor-free conditions, has high levels of
tyrosine phosphorylated membrane proteins, and has the
capacity to invade basement membranes and grow under
anchorage-independent conditions [10–12]. Thus,
SUM-52PE cells, which have amplifications of both
FGFR1 and FGFR2 genes, exhibit all of the important hall-
marks of highly malignant cells. In order to understand
better the important molecular alterations that lead to this
transformed phenotype, we examined the contribution of
FGFR2 overexpression to these characteristics. Isolation
and characterization of individual FGFR2 isoforms is an
important first step in identifying the contribution of this
receptor to cell transformation. Therefore, SUM-52PE was
used as a model to study the diversity of FGFR2 expres-
sion in a breast cancer cell line that has true amplification
and overexpression of the FGFR2 gene.
Materials and methods
Southern blot analysis
Genomic DNA (10 µg) was digested with Hind III, and
restriction fragments were separated on an agarose gel
and transferred by standard methods to a nylon mem-
brane. The Southern blot was probed with either FGFR1
or FGFR2, generated by RT-PCR of MCF-10A cell RNA.
The specific primers used in the RT-PCR reaction were as
follows: 5′-CAAACCCAACCGTGTGACCAAAGTG-3′ and
5′-CGTGCGAGGCCAAAGTCTGCTATCT-3′ for FGFR1;
and 5′-GGTCGTTTCATCTGCCTGGT-3′ and 5′-CCTTC-
CCGTTTTTCAGCCAC-3′ for FGFR2. The RT-PCR reac-
tion was carried out as described below.
Northern blot analysis
RNA (10 µg) from a normal HME cell line (MCF-10A) and
a panel of HBC cell lines (SUM-52, -149, -185 and -206)
was run on a 1% agarose gel containing formaldehyde,
and then transferred to a Nytran membrane (Schleicher &
Schuell, Keene, NH, USA). The membrane was probed
with full-length FGFR2 C1-#1 isolated from the
SUM-52PE HBC cell line. Probe (50 ng) was labeled
using a random priming kit (Gibco BRL, Grand Island, NY,
USA) with 5 µCu α-P32-dCTP at 25°C for 2 h. Unlabeled
α-P32-dCTP was removed by centrifugation of the probe
through a Quik-Spin (Roche Molecular Biochemicals,
Indianapolis, IN, USA) column at 1100 revolutions/min for
4 min. Labeled probe (20 × 106 cpm) was boiled at 100°C
for 5 min and then used to probe the Northern blot
overnight at 42°C. Prehybridization of the membrane
occurred for 2.5 h at 42°C.
Fibroblast growth factor receptor-2 Western blots
Cells were rinsed twice with ice-cold Hanks’ balanced salt
solution (Gibco BRL) and then lysed on ice with a buffer
consisting of 50 mmol/l Tris-HCl (pH 8.5); 150 mmol/l
NaCl; 1% Nonidet P-40 (ICN Biomedical, Inc, Aurora, OH,
USA); 5 mmol/l ethylene diamine tetra-acetic acid supple-
mented with 5 mmol/l sodium orthovanadate; 50 µg/ml
phenylmethysulfonyl fluoride; 20 µg/ml aprotinin; and
10 µg/ml leupeptin. Lysates were spun at 20 800 g at 4°C
for 10 min and then analyzed for protein using a modified
Lowry’s method. Whole-cell lysates were resolved on
7.5% polyacrylamide gels, transferred to PVDF membrane
(Millipore Corporation, Bedford, MA, USA), and probed
with an anti-FGFR2 antibody (Santa Cruz Biotechnology,
Inc, Santa Cruz, CA, USA), an anti-FGFR2 antibody pre-
conjugated with a competitive peptide (Santa Cruz
Biotechnology, Inc) at room temperature for 2 h, or an anti-
Flag antibody (M2 antibody; Sigma, St Louis, MO, USA).
Reverse transcription polymerase chain reaction analysis
of exon IIIb/c expression
FGFR2 variants were amplified using exon III specific
primers: 5′-CCCGGGTCTAGATTTATAGTGATGCCCA-
GCCC-3′ for FGF-FB; and 5′-CCCGGGGAATTCAC-
CACCATGCAGGCGATTAA-3′ for FGF-RB [25]. RT-PCR
amplification was carried out by use of the SuperScript
One Step RT-PCR system (Gibco BRL) with the addition
of 1 µl Expand High Fidelity enzyme (Roche Molecular Bio-
chemicals). RT was carried out at 50°C for 30 min, fol-
lowed by 94°C for 3 min. The PCR reaction was for 25
cycles of 94°C for 30 s, 65°C for 30 s, and 72°C for 1 min,
and final extension at 72°C for 7 min. Singly, Ava I and
Hinc II digestion of the RT-PCR product was performed
overnight at 37°C, and then run on 3% NuSieve 3:1
agarose gel (FMC Bioproducts, Rockland, ME, USA).
Isolation of fibroblast growth factor receptor 2 cDNA
clones
RNA was isolated from the SUM-52PE cell line using the
Trizol isolation technique (Gibco BRL). RT-PCR amplifica-
tion of FGFR2 was carried out by use of the SuperScript
One Step RT-PCR system (Gibco BRL) with the addition
of 1 µl Expand High Fidelity enzyme (Roche Molecular Bio-
chemicals). RT was carried out at 50°C for 30 min, fol-
lowed by 94°C for 3 min. Amplification of FGFR2 was
carried out using gene-specific primers: 5′-ATGCCCGTA-
GAGGAAGTGTG-3′ for FGFR2 upstream; 5′-AACG-
CACGTCCACCTTGAGTCCT-3′ for C1/C2-specific
downstream; and 5′-CTATTACTTGTCATCGTCGTCCTT-
GTAGTCGATCTCATTGGTTGTGAG-3′ for C3-specific
downstream. This was done for 40 cycles of denaturation
at 94°C for 15 s, annealing at 55°C for 30 s, and elonga-
tion at 72°C for 3 min, and final extension at 72°C for
7 min. FGFR2 cDNA was then digested with Sal I/Xba I
and ligated into the pZ vector at 14°C overnight using T4
DNA ligase. The ligation reaction was transformed into
SURE Escherichia coli cells (Stratagene, La Jolla, CA,
USA) as recommended.
Transfection of 293 cells
One-hundred-millimeter dishes of 293 cells at 50% sub-
confluence were transfected with 20 µg plasmid contain-
ing individual cDNA clones isolated from the SUM-52PE
cell line using the calcium phosphate method. Briefly, 293
cells were incubated in 10% Dulbecco’s modified eagle
medium with 10 mmol/l chloroquine for 5–10 min. A reac-
tion mix of 20 µg cDNA, 1 × Hepes-buffered saline, and
CaCl2 (JT Baker, Phillipsburg, NJ, USA) was put into 293
dishes. Media was changed 6–8 h after transfection and
whole-cell lysates were prepared 48 h after transfection,
as described above. Whole-cell lysates (100 µg) were
resolved on 7.5% polyacrylamide gels, transferred to a
polyvinylidene fluoride membrane, and probed with the
anti-FGFR2 antibody (Santa Cruz Biotechnology, Inc) or
an anti-Flag antibody (M2 antibody, Sigma).
Sequencing of fibroblast growth factor receptor 2 variants
Plasmid cDNA for individually isolated FGFR2 isoforms
was prepared and submitted to the University of Michigan
DNA Sequencing core with a series of FGFR2-specific
primers, as well as vector-specific primers. The sequenc-
ing of all FGFR2 variants was performed in both a 5′ and a
3′ direction, with the exclusion of the transmembrane
domain, which was shown to be highly conserved
between isoforms.
Results
Amplification of fibroblast growth factor receptor 2 in
SUM-52PE cells
In previous experiments, we found by comparative
genome hybridization analysis that SUM-52PE cells have
large amplifications in the genomic regions of chromo-
somes 8 and 10, containing the FGFR1 and FGFR2
genes, respectively [14]. In order to characterize the
amplification of these candidate breast cancer oncogenes,
Southern blot analysis was performed on the HBC cell line
SUM-52PE and other breast cancer cell lines [14]. The
results of the Southern blot showed fivefold amplification
of the FGFR1 gene and a 12-fold amplification of the
FGFR2 gene in SUM-52PE cells, as compared with other
breast cancer cell lines that do not have genomic amplifi-
cations in these regions (Fig. 1).
Overexpression of fibroblast growth factor receptor 2
transcript in SUM-52PE cells
Because gene amplification often involves large genomic
regions that contain many genes, Northern blot analysis
was performed to determine whether the observed amplifi-
cations of FGFR1 and FGFR2 correlated with transcript
overexpression. Northern blot analysis of SUM-52PE
showed FGFR2 transcripts to be highly overexpressed
compared with other breast cancer cell lines (Fig. 2a,
lanes 2–5) and normal HME cells (Fig. 2a, lane 1). Several
overexpressed bands of approximately 6.3, 5.0, 4.0, and
2.8 kb were observed in SUM-52PE cells. The most
prominent band, at 2.8 kb, was so abundant that it was
difficult to discern other individual bands clearly. FGFR1
transcript overexpression, on the other hand, was not
detected in SUM-52PE (data not shown).
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Overexpression of fibroblast growth factor receptor 2
variants in SUM-52PE cells
FGFR2 has been reported to be alternatively spliced,
resulting in translation of multiple FGFR2 isoforms.
Because Northern blot experiments demonstrated a
number of different FGFR2 isoforms, Western blot analy-
sis was performed to examine the number and level of
expression of FGFR2 protein(s). The results showed that
both normal HME and HBC cells (SUM-44PE,
SUM-52PE, and others not shown) expressed two iso-
forms of FGFR2 of 135 and 95 kDa (Fig. 2b, left panel,
lanes 1–3, polypeptides labeled common). Interestingly,
as compared with HME and other HBC cells, the
SUM-52PE cell line greatly overexpressed not only these
two polypeptides, but also overexpressed two unique iso-
forms of FGFR2 – 85 and 109 kDa polypeptides – as well
as several smaller polypeptides in the 46–53 kDa range
(Fig. 2b, left panel, lane 3, labeled unique). Use of a com-
petitive peptide preconjugated with the anti-FGFR2 anti-
body confirmed that these bands were specific FGFR2
polypeptides (Fig. 2b, right panel). Use of an antibody
isotype control also confirmed the same nonspecific
bands as those that were identified by use of the competi-
tive peptide (data not shown).
It is important to note that the polyclonal anti-FGFR2 anti-
body used in these experiments was created against a
peptide derived from the C1 carboxyl terminus of FGFR2.
Thus, this antibody only recognizes FGFR2 isoforms that
express this carboxyl terminus. Because antibodies that
recognize FGFR2 isoforms that express either the C2 or
C3 carboxyl termini are not currently available, the results
of the Western blot analysis of SUM-52PE cells under-
represents the actual number of different FGFR2 proteins
expressed in this cell line.
Preliminary characterization of fibroblast growth factor
receptor 2 expression in SUM-52PE cells
To begin to characterize the FGFR2 transcripts that were
present in SUM-52PE cells, PCR-based assays were per-
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Figure 1
Amplification of FGFR1 and FGFR2 in SUM-52PE cells. (a) Genomic
DNA from four breast cancer cells lines (SKBR3, SUM-52PE,
SUM-44PE, and T47D) were compared by Southern blot for FGFR1
expression. (b) Genomic DNA from three breast cancer cell lines
(SKBR3, SUM-52PE, and SUM-44PE) were compared by Southern
blot for FGFR2 expression.
Figure 2
Analysis of FGFR2 expression in HBC and HME cells. (a) A Northern
blot probed with full-length FGFR2 is shown. A glyceraldehyde
3′-phosphate dehydrogenase (GAPDH) probe was used to normalize
RNA levels. Cell lines shown are as follows: normal HME cell line
(MCF-10A, lane 1) and HBC cell lines (lanes 2–5). Size of visualized
bands are marked according to kilobase. (b) Whole-cell lysates were
immunoblotted with an anti-FGFR2 antibody in the absence (left panel)
or presence (right panel) of a competitive peptide. Breast cancer cell
lines are in lanes 2 and 3, and a normal HME sample (MCF-10A) is in
lane 1. All cell lines expressed two ‘common’ FGFR2 variants (of 95
and 135 kDa), whereas SUM-52PE expressed at least three ‘unique’
variants (of 46–53, 85, and 109 kDa), as determined by comparison
with nonspecific bands (NS; right panel).
formed to estimate the relative proportions of transcripts
containing exon IIIb versus IIIc, and the proportion of
C1/C2 variants as compared with C3 variants.
RT-PCR analysis using exon III-specific primers was per-
formed on SUM-52PE mRNA, followed by restriction frag-
ment analysis to determine the presence of exon
IIIb/c-expressing variants [25]. Exon IIIb contains one
unique Ava I site, whereas exon IIIc contains two Hinc III
sites. Therefore, the proportion of Ava I digest fragments
to Hinc III digest fragments allows for the determination of
the proportion of IIIb to IIIc variants present. Using this
method, SUM-52PE cells were found to express only IIIb
isoforms, because the PCR product obtained was com-
pletely digested by Ava I, whereas Hinc III failed to cut any
of the amplified product (Fig. 3a).
C1/C2 variants were amplified using a primer specific to
the 3′-noncoding region, whereas C3 variants were ampli-
fied using a primer specific for the C3 3′-noncoding
region. Results of this analysis indicated the presence of
all three types of variants in this cell line, although the
C1/C2 variants (Fig. 3b; lanes 1 and 2) appeared to be
more abundant than the C3 variants in SUM-52PE
(Fig. 3b; lanes 3 and 4).
Isolation and analysis of alternatively spliced fibroblast
growth factor receptor 2 variants
The PCR-based approach just described suggested that
SUM-52PE cells express exclusively IIIb type receptors,
which can contain any of the three carboxyl termini. The
data also suggested that C1 and C2 variants are more
common than receptors with the C3 terminus. In order to
characterize definitively the range of FGFR2 variants
expressed by SUM-52PE cells, individual isoforms were
cloned and sequenced from SUM-52PE RNA. To isolate
specific FGFR2 cDNAs, C1/C2- or C3-specific primers
were used in combination with a primer for the 5′ end of
the gene. RT-PCR amplified FGFR2 products were puri-
fied and ligated into the bicistronic vector pZ. Individual
clones containing insert were characterized by restriction
digest analysis, sequencing, and transient transfection into
293 cells.
FGFR2 cDNA clones isolated from RNA derived from
SUM-52PE cells were highly variable and differed with
respect to number of Ig-like loops expressed, the pres-
ence or absence of the acid box, and the expression of
C1, C2, or C3 carboxyl termini. As predicted from the
PCR experiments, all FGFR2 variants isolated from
SUM-52PE expressed the IIIb exon.
Four different FGFR2-C1 clones were isolated and
sequenced (Fig. 4). The largest clone, C1-#38, was a full-
length FGFR2-IIIb isoform, which was previously identified
in the literature as KGF receptor [3,26]. C1-#38 contained
three Ig-like domains, the characteristic acid box, and the
C1 exon in the carboxyl terminus. The other three C1 iso-
forms contained two Ig-like domains, as well as exon IIIb,
but differed with respect to the rest of their extracellular
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Figure 3
Preliminary characterization of FGFR2 expression in SUM-52PE cells.
(a) Exon III-specific primers were used in RT-PCR of SUM-52PE RNA.
RT-PCR product was then digested with Ava I or Hinc II at 37°C
overnight and then resolved on a 3% NuSieve gel. Exon IIIb contains
one unique Ava I site, whereas exon IIIc contains two Hinc II sites, and
therefore the proportion of Ava I digest fragments to Hinc II digest
fragments determines the proportion of IIIb to IIIc variants present. The
presence of 269 and 188 bp fragments generated by Ava I digestion
(lane 2) and lack of Hinc II digested products (lane 3) confirms the
exclusive presence of exon IIIb in FGFR2 variants in the SUM52-PE
cell line. (b) SUM-52PE mRNA was reverse transcribed using an oligo
dT primer, and then amplified using a 5′-FGFR2-specific primer and a
3′-specific primer for C1/C2 or C3. Equimolar amounts of primer were
used in the PCR reaction, and then 2 or 5 µl of PCR product were
compared on a 0.8% agarose gel. Lane 1, 2 µl C1/C2 product; lane 2,
5 µl C1/C2 product; lane 3, 2 µl C3 product; lane 4, 5 µl C3 product.
domains. C1-#8 contained two Ig-like domains and the
acid box in the extracellular region. C1-#1 expressed two
Ig-like domains, but was lacking part of the extracellular
region corresponding to the acid box. This type of deletion
has previously been identified as an FGFR2-IIIc variant,
Bek103 [27]. C1-#10 was a unique variant that expressed
two Ig-domains and the acid box, but contained a unique
deletion of the 5′ region of the receptor corresponding to
the signal sequence. The functional significance of this
type of deletion has yet to be determined.
Two FGFR2-C2 clones were isolated from the SUM-52PE
cell line (Fig. 4). Clone C2-#19 contained three Ig-like
domains, the acid box, and the C2 exon in the carboxyl
termini. Clone C2-#5 contained two Ig-like domains, but
was missing part of the extracellular domain, which is
similar to, but smaller than the deletion characterized for
clone C1-#1. A clone identical to C2-#5 has previously
been identified in the literature as human K-sam C2, a
variant isolated from the KATO-III human stomach cancer-
derived cell line [4]. Both K-sam and clone C2-#5 are
missing the same 89 amino acid sequence in the 5′ region
of FGFR2 corresponding to the first Ig-like domain region.
Three C3 clones were isolated and sequenced, two of
which have not previously been described in the literature
(Fig. 4). C3-#4, a previously described FGFR2 variant,
contained three Ig-like domains and the acid box, and was
considered a full-length C3 clone [4]. Clone C3-#3 con-
tained two Ig-like domains, but the lack of the acid box
makes this a unique C3 variant. C3-#5 was missing the
first two Ig-like domains and the acid box, but did contain
the third Ig-like domain. This FGFR2 isoform also has not
previously been reported.
Because FGFR2 transcripts from HME cells were not
detectable by Northern blot, and because HME cells
express FGFR2 protein that is detectable by Western blot,
experiments were performed to isolate FGFR2 clones from
RNA derived from normal HME cells. After two cycles of
RT-PCR and subsequent cloning into pZ, three different
FGFR2 isoforms were obtained. As with the SUM-52PE
cells, all three isoforms cloned from HME cells contained
exon IIIb. Two clones with C1 carboxyl termini were iso-
lated, one of which was full length (the same as clone
C1-#38 from SUM-52PE) and the second was missing the
first Ig loop (the same as clone C1-#8). One clone contain-
ing the C2 terminus was isolated that was otherwise a full-
length isoform (the same as clone C2-#19).
Fibroblast growth factor receptor 2 protein expression in
transfected 293 whole cell lysates
To assess the ability of the various FGFR2 isoforms iso-
lated from SUM-52PE cell RNA to synthesize protein, and
to determine which FGFR2 clones direct the synthesis of
protein isoforms detected in Western blots, 293 cells
were transiently transfected with individual FGFR2 iso-
forms using the bicistronic pZ expression vector and ana-
lyzed by Western blot. As can be seen in the left panel of
Figure 5a, all four C1-containing isoforms expressed
protein in 293 cells and each clone gave rise to an FGFR2
isoform with distinct molecular size. Similarly, all three C3-
containing clones expressed protein in 293 cells (Fig. 5b).
C3-containing isoforms were visualized using a flag anti-
body that detects an epitope tag incorporated into the
design of the C3-specific primer. As can be seen from the
right panel of Figure 5b, the molecular sizes of the C3 vari-
ants correspond to what would be predicted on the basis
of the size of the individual clones. C3-#4 is full length at
the amino terminus, C3-#3 is missing the first Ig loop and
the acid box, and C3-#5 is missing the first Ig loop, the
acid box and the second Ig loop.
Unfortunately, we cannot assess protein synthesis from
any of the C2-containing clones at this time. Because C1
and C2 are derived from the same exon, and because we
used a single primer to clone both C1- and C2-containing
variants, which did not contain an epitope tag, we are cur-
rently unable to detect FGFR2-C2 proteins.
As shown in Figure 2b, two FGFR2-C1 proteins (of 95
and 135 kDa) are commonly detected in SUM-52PE cells,
HME cells, and other breast cancer cell lines. This is in
accord with the observation that both C1 variants cloned
from HME cells were also cloned from SUM-52PE cells.
Thus, the data suggest that the common band that
migrates at 135 kDa represents the glycosylated version
of the full-length FGFR2-C1 (C1-#38: Fig. 5a; lanes 1 and
4). Similarly, the second common band that migrates at
95 kDa is likely derived from clone C1-#8, which is
missing the first Ig loop (Fig. 5a; lanes 1 and 3). Clone
C1-#1 was highly expressed in 293 cells and resulted in
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Figure 4
Isolated and sequenced FGFR2 isoforms from SUM-52PE. Isolated
FGFR2 variants had variable expression of two to three Ig-like
domains, as well as the characteristic acid box in the extracellular
portion of the molecule. Variability between isolated clones also
existed in the intracellular portion of the molecule, where alternative
splicing of exons C1/C2 or C3 created either a full-length carboxyl
termini (C1), or truncated versions (C2 or C3).
the detection of multiple immunoreactive proteins with a
range of sizes (Fig. 5a; lane 2). It is possible that this
isoform, which is missing both the first Ig loop and the
acid box, is responsible for some of the high- and low-mol-
ecular-weight bands detected in SUM-52PE Western
blots, although more work will be required to definitively
demonstrate this. The contribution of clone C1-#10,
which was only weakly expressed in 293 cells, to FGFR2
protein expression in SUM-52PE cells cannot be deter-
mined at this time (Fig. 5a; lane 5).
As described above, clone C1-#38 encodes the full-
length FGFR2-IIIb/C1 form of the receptor and is
expressed at the message level in normal cells and all
breast cancer cells examined, including SUM-52PE.
However, SUM-52PE cells also have an overexpressed
band at 109 kDa, which was also detected in 293 cells
transfected with clone C1-#38 (Fig. 5a; lane 4) and in
HME cells transduced with this clone (not shown). This
band was not detected in HME cells or any other breast
cancer cells (Fig. 2b; left panel). The molecular size of this
band corresponds to the size of the mature, non-
processed, full-length protein, suggesting that the
135 kDa band corresponds to the fully glycosylated form
of the protein. The ability to detect this 109 kDa non-
processed form of full-length FGFR2-IIIb/C1 only in
SUM-52PE cells and cells transduced with clone C1-#38
suggests that the protein is rapidly glycosylated in cells
that express physiologic levels of FGFR2. By contrast, in
cells that overexpress FGFR2, the 109-kDa nonglycosy-
lated protein accumulates in the cell and is detectable by
Western blot as one of the unique bands shown in
Figure 2b. Thus, the detection of unique bands in Western
blots derived from SUM-52PE cells reflects not only differ-
ences in isoform synthesis at the message level, but also
differences in protein processing that occurs when the
protein is highly overexpressed. At present, the functional
consequences of the accumulation of nonglycosylated
FGFR2 are not known.
Discussion
The progression of cells from the normal to neoplastic
state is a multistep process that involves alterations in mul-
tiple signaling pathways. Both epidermal growth factor
receptor and erbB-2 have been identified as signaling
molecules that play a dominant role in breast cell transfor-
mation [28,29]. There is an extensive amount of evidence
for erbB-2 as a breast cancer gene that is overexpressed
in approximately 30% of breast cancer cases [13]. The
identification of other breast oncogenes that function in
the remaining 70% of cases is an ongoing challenge, as is
establishing a causal role for such oncogenes in HME cell
transformation.
Large regions of gene amplification in cancer cells can be
detected by techniques such as comparative genomic
hybridization and high-density arrays, which helps to local-
ize areas that may contain functional oncogenes. FGFR1
and FGFR2, which were previously established as candi-
date breast cancer oncogenes, were found to be amplified
within large amplicons on 8p11 and 10q26, respectively,
in the breast cancer cell line SUM-52PE [14]. Previous
studies [5–7] have shown that the FGFR2 gene is ampli-
fied in about 5–10% of cases. Because genes can be
amplified without being overexpressed [14], we chose to
examine whether FGFR2 may be an important oncogene
in this breast cancer cell line by examining its expression
at the mRNA and protein levels. Our results showed that
SUM-52PE cells overexpressed many alternatively spliced
forms of FGFR2 at both the transcript and protein level, as
compared with normal mammary epithelial cells. By con-
trast, FGFR1 is not expressed in SUM-52 cells.
In contrast to SUM-52PE cells, FGFR2 expression at the
message level is very low in HME cells. Indeed, even pro-
longed exposure of Northern blots to film did not allow the
visualization of FGFR2 message in normal cells. However,
Western blots did indicate the presence of FGFR2 protein
in HME cells. To resolve this apparent paradox, two
rounds of RT-PCR were performed using HME cell-
derived RNA, which resulted in the isolation of three alter-
natively spliced forms of FGFR2 message, each of which
expressed the IIIb exon. The predicted protein products of
these clones correspond to that which was observed in
Western blots.
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Figure 5
Transient expression of FGFR2 clones isolated from SUM-52PE. (a)
Whole-cell lysates from 293 cells that had been transiently transfected
with individual FGFR2 clones were immunoblotted with an anti-FGFR2
antibody (lanes 2–5). Whole-cell lysate from the SUM-52PE breast
cancer cell line was loaded in lane 1 as a positive control, whereas
whole-cell lysates from a mock transfection of 293 cells was loaded in
lane six as a negative control. (b) Whole-cell lysates from 293 cells
that were transiently transfected with individual FGFR2-C3 clones
containing a Flag sequence were immunoblotted with an anti-Flag
antibody (lanes 1, 2, and 4). Whole-cell lysates from a mock
transfection of 293 cells were loaded in lane 3 as a negative control.
The variability in FGFR2 isoform expression is complex
and involves exon IIIb/c, which encodes the second half of
the third Ig-like loop, variations in the carboxyl terminal end
of the receptor involving the C1/C2 or C3 domains, and
variable expression of the Ig-like loops and acid box in the
extracellular portion of the receptor.
Alternative splicing of the FGFR2 mRNA that encodes the
carboxyl terminus has been shown to involve at least two
different exons, which can produce at least three different
variants. The C1- and C2-type carboxyl termini are
encoded by the same exon, having two different splice
acceptor sites, whereas the C3-type carboxyl terminus is
encoded by a separate exon [4]. The biologic significance
of the full-length carboxyl terminus (C1), as compared with
the truncated variant found primarily in tumorigenic
samples (C3), has been studied in NIH3T3 transfection
assays. The IIIb variants KGF receptor (C1) and K-sam C3
were both able to produce transformed foci, growth in soft
agar and tumorigenicity in nude mice as compared with
full-length IIIc variants of FGFR2 and FGFR1, which were
not transforming [4]. The question of whether C3 variants
are more transforming than C1 variants remains to be
determined conclusively, because the number of trans-
formed foci obtained using K-sam C3 was only threefold
greater than that obtained using KGF receptor (C1) vari-
ants. A significant difference between the C3 and C1
termini is that the former does not contain the binding site
for phospholipase Cγ. Thus, the ability of the variants of
FGFR2 containing the C3 terminus to transform 3T3 cells
suggests that signaling through this pathway is not neces-
sary for FGFR2 IIIb to act as an oncogene.
The panel of FGFR2 isoforms isolated from SUM-52PE
includes several unique and previously unreported iso-
forms. The first of these unique variants, C1-#10, contains
a large deletion of the 5′ region that includes the first
Ig-like domain as well as the signal sequence, which could
have interesting cellular localization and cell signaling
properties due to the absence of part of the signal
sequence. Clones C3-#3 and C3-#5 have not previously
been reported and are missing the first Ig-like domain and
acid box. C3-#5 is also missing the second Ig-like domain.
The characterization of these three unique isoforms may
build upon the findings of others concerning the trans-
forming potential of FGFR2 variants [4]. In particular,
because it has been demonstrated that C3-IIIb variants
may have more transforming activity than C1-IIIb variants,
differences between the three C3 clones we have isolated
may provide information on the influence of particular
structural domains on transforming potential.
Previous studies that examined FGFR2 expression in
prostate cancer have suggested that a change in the
expression from the exon IIIb to IIIc isoform correlates with
a progression from an androgen-sensitive to an androgen-
insensitive state. RT-PCR analysis on the SUM-52PE
breast cancer cell line showed that this cell line exclusively
expressed the IIIb FGFR2 isoform (Fig. 3). Exon IIIb
expression was also exclusively found in normal luminal
HME cells (data not shown). This suggests that exon IIIb
to IIIc switching is not necessary for FGFR2 to act as an
oncogene when the gene is amplified. Rather, overexpres-
sion of one of the common IIIb isoforms or one of the
novel variants may be important in driving transformation
of HME cells. Ongoing studies are aimed at characterizing
the transforming ability of individual FGFR2 isoforms
obtained from SUM-52PE cells. These studies will directly
test the hypothesis that specific FGFR2 isoforms have
transforming activity towards HME cells and will compare
variants with the different carboxyl termini. Overexpression
of the C1-#38 and C3-#5 FGFR2 clones has been suc-
cessfully accomplished in both the MCF-10A and H16N2
HME cell lines, and these cells have acquired phenotypes
that distinguish them from parental cells (to be described
in detail in a separate paper that is in preparation). Thus,
by overexpressing FGFR2 isoforms in a physiologically rel-
evant system, we hope to determine the isoform(s) that
acts in a dominant way in the process of cell transforma-
tion, as well as to determine whether different regions
present in individual clones drive specific phenotypes
associated with transformation.
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